Navigation Links
Nutraceutical Reports 2008 Fiscal Year End Results
Date:11/20/2008

ent assets, net $55,577 $51,534 Property, plant and equipment, net 52,356 39,506 Goodwill 37,632 38,978 Other non-current assets, net 16,099 16,384 $161,664 $146,402 Liabilities and Stockholders' Equity Current liabilities $19,239 $20,275 Long-term liabilities 28,965 20,208 Stockholders' equity 113,460 105,919 $161,664 $146,402 NUTRACEUTICAL INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited; dollars in thousands, except per share data) Three months ended Twelve months ended September 30, September 30, 2008 2007 2008 2007 Net sales $40,899 $39,902 $166,885 $156,548 Cost of sales 18,914 18,429 76,106 71,622 Gross profit 21,985 21,473 90,779 84,926 Operating expenses Selling, general and administrative 16,434 16,217 66,973 61,905 Amortization of intangible assets 179 161 701 391 Impairment of goodwill and intangible asset 2,875 450 2,875 450 Income from operations 2,497 4,645 20,230 22,180 Interest and other (income)/expense, net 262 443 1,270 1,257 Income before provision for income taxes
'/>"/>
SOURCE Nutraceutical International Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
2. Nutraceutical to Present at Canaccord Adams Healthy Living Conference
3. Nutraceuticals could prevent diabetes
4. Nutraceutical Reports Q3 Results
5. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
6. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
7. Berkeley Premium Nutraceuticals Pushes Forward
8. Direct Response TV Course on Nutraceutical/Cosmeceutical Products to Premiere in New York City
9. Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer
10. Nutraceutical Reports Fiscal 2008 Q1 Results
11. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...y could shape new treatments for secondary pneumon...swire/ -- Scientists at St. Jude Children,s Resear...atment for bacterial pneumonia following influenza...azithromycin, which kill bacteria by inhibiting th...tandard first-line treatment with the "beta-lactam...
(Date:1/8/2009)... hurtful comments, study suggests , , T...erestimate how strongly they would react to racist...e percent of study participants at York University...ment with a white person rather than a black one, ...bout the black person when he left the room. ,...
(Date:1/8/2009)...ldren,s Research Hospital have demonstrated a more...wing influenza. They found that the antibiotics cl... inhibiting their protein synthesis, are more effe...e "beta-lactam" antibiotic ampicillin, which cause...g is important because pneumonia, rather than the ...
(Date:1/8/2009)...PRNewswire-FirstCall/ -- Hanger Orthopedic Group, ...roughout the fourth quarter of 2008 it acquired Ma...ountain Orthotic-Prosthetics Center, Riessen,s Ort... Orthotics & Prosthetics, and Orthopedic Rehab...tient care centers to existing markets in Maine, L...
Breaking Medicine News(10 mins):Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Many Turn Blind Eye to Racism 2Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2
...apeutic regimens are effective in suppressing HIV ... treatment may be complicated by development of dr...e // continued concerns over the safety of interru...clinical practice interrupt therapy for reasons re...
... reported at a seniors' home in Toronto and expert... caused the death of four residents at the home. I...here was // no cause to fear an outbreak and stres...e, "This isn't a pandemic by any means, but there ...
...arch in the areas of fetal imaging focus on modali...t women, their unborn babies and newborns with MR ...les diagnosis and treatment of many // disorders t...elayed intervention.. Fetal MRI is usually perform...
...rized by insulin resistance and/or abnormal insuli...inues to expand unabated throughout the world. The...to decreased physical activity, decreased function..., preexisting glucose and insulin abnormalities, a...
Other Medicine News:Health News:Cigarette Smoking Leads To Development Of Type 2 Diabetes In Patients With Coronary Artery Disease 2
(Date:1/8/2009)...O, Jan. 8 If you are taking prescr...re not alone. Half of the people taking,prescript...ons are,varied -- they forget, are busy with othe.... Noncompliance has been called the Achilles heel ...verett Koop commented, "Drugs don,t,work in peopl...
(Date:1/8/2009)...reated at the initial dose in an ongoing Phase Ib ...ecline after three days , , Conference Call Tod...wire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (N...irst cohort of an ongoing Phase Ib clinical trial ...oside polymerase inhibitor. ANA598 was very well-...
(Date:1/7/2009)...enn., Jan. 7 Scientists...a high likelihood of relapse in children with acut...rchers caution that further research is needed to ...or IKAROS, lead to leukemia relapse, the finding...ostic tests to assess the risk of treatment failur...
(Date:1/7/2009)... Md., Jan. 7 ImQuest Life Sciences...ND application to the Food and Drug Administration...pyrimidinedione HIV inhibitor IQP-0410. ImQuest an...first quarter of 2009. IQP-0410 is a novel small m... nonnucleoside reverse transcriptase inhibitor (NN...
Breaking Medicine Technology:Good Medicine: Smarter Smartphones for People With Chronic Disease 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 1Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 3Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 1Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 2Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 3Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 5WallSt net Announces Upcoming Interview With CEO of ReBuilder Medical Technologies 2249 1WallSt net Announces Upcoming Interview With CEO of ReBuilder Medical Technologies 2249 2LeMaitre Vascular Appoints Russell D Hays to Its Board of Directors 2247 1LeMaitre Vascular Appoints Russell D Hays to Its Board of Directors 2247 2
...oved by FDA for long-term,maintenance treatment of...nebulized formoterol fumarate provides improved lu...nhanced patient quality of,life, and positive safe...ta presented at the,International Conference of th... Perforomist™ (formoterol fumarate),Inhalati...
...The U.S. Food and Drug Administration,(FDA) is awa...(rosiglitazone), a drug approved to treat type 2 d...ls have shown that there is a,potentially signific...-related deaths in patients taking Avandia. Howeve...term clinical trials of,Avandia, including an inte...
Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7FDA Issues Safety Alert on Avandia 2FDA Issues Safety Alert on Avandia 3
Aluminum Stylette 16 with Adjustable Stop.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Aluminum Stylette 16.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Medicine Products: